Previous 10 |
home / stock / mllcf / mllcf news
AbbVie (NYSE: ABBV ) unit Allergan has received a Complete Response Letter (CRL) from the FDA regarding its marketing application seeking approval of DARPin drug abicipar pegol for the treatment of neovascular age-related macular degeneration (wet AMD). More news on: AbbVie Inc., Molecul...
The FDA and European Medicines Agency have accepted for review marketing applications submitted by Allergan ( AGN -0.2% ) seeking approval for DARPin drug abicipar pegol for the treatment of neovascular age-related macular degeneration (wet AMD). The respective action dates will be in mi...
Results from a 28-week open-label study, MAPLE, evaluating Allergan (NYSE: AGN ) and licensor Molecular Partners' ( OTCPK:MLLCF ) abicipar in 123 patients with age-related neovascular macular degeneration (nAMD) showed an improved safety profile after the manufacturing process was modifie...
Molecular Partners AG ( OTCPK:MLLCF ): FY GAAP EPS of -CHF1.75. More news on: Molecular Partners AG, Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Molecular Partners AG Company Name:
MLLCF Stock Symbol:
OTCMKTS Market:
Molecular Partners AG Website:
Proof-of-concept of Switch-DARPin platform established in vivo , enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with ...
MP0712, a 212 Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano Med Positive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profile First-in-human study in planning...
Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment Favorable and manageable safety profile observed at all tested dose levels Weekly and three-weekly dosing schedules established, supported by pharmacokinetics and pharmac...